.jpeg)
{{ variable.name }}
Semaglutide tablets can effectively control blood sugar levels by simulating the action mechanism of human incretin, enhancing insulin secretion, inhibiting glucagon secretion, and delaying gastric emptying.
Common name: Semaglutide
1. As an auxiliary treatment for diet and exercise, it is used to improve blood sugar control in adults with type 2 diabetes.
2. Restricted use of :
Not recommended as the first choice treatment for patients with poor diet and exercise control.
Not studied in patients with a history of pancreatitis.
Not suitable for the treatment of type 1 diabetes or diabetic ketoacidosis.
1. 3mg tablet.
2. 7mg tablets.
3. 14mg tablet.
4. Active ingredient: semaglutide (GLP-1 receptor agonist).
5. Excipients: magnesium stearate, microcrystalline cellulose, povidone, sodium cholate (SNAC).
1. Initial dose of : 3mg once a day for 30 days.
2. Maintenance dose : increase to 7mg once a day after 30 days.
3. Intensive dose : If additional blood sugar control is needed, it can be increased to 14mg once a day after 30 days.
4. Key usage of :
Take it on an empty stomach in the morning. Fast at least 30 minutes before and 30 minutes after taking the medicine.
Only take with ≤120mL of water. Swallow the whole tablet and do not chew/break it.
1. Handling missed doses : Skip the dose of the day and take the medicine as originally planned the next day.
2. Switching treatment :
Switching from RYBELSUS 14mg to OZEMPIC® injection: 0.5mg once a week can be started the next day.
Converting from OZEMPIC® 0.5 mg to RYBELSUS: Start 7 mg or 14 mg within 7 days of last injection.
1. Medication time : It must be taken on an empty stomach. Taking it with food/drinks will reduce the efficacy of the medicine.
2. Gastrointestinal reactions : Nausea, vomiting, and diarrhea are common, mostly occurring during the dose escalation period.
3. Drug interaction :
Dose adjustment is required when used in combination with insulin or sulfonylureas to prevent hypoglycemia.
Delayed gastric emptying may affect the absorption of other oral medications (eg, levothyroxine needs to be monitored).
1. Pregnant women should stop taking at least 2 months before pregnancy (long half-life).
2. U200c during lactation: prohibited (the drug may be excreted in breast milk).
3. Renal insufficiency : No dosage adjustment is required.
4. Hepatic insufficiency : No dose adjustment is required.
5. Elderly : Age does not affect pharmacokinetics.
1. Common (≥5%) : nausea (20%), abdominal pain (11%), diarrhea (10%), decreased appetite (9%), vomiting (8%), constipation (5%).
2. Serious adverse reactions :
Risk of thyroid C-cell tumors (animal experiments).
Pancreatitis (incidence rate 0.1%/year).
Complications of diabetic retinopathy.
1. Personal/family history of medullary thyroid cancer (MTC).
2. Multiple endocrine neoplasia syndrome type 2 (MEN2).
3. Are allergic to semaglutide or any excipients.
U200c should be used with caution:
1. Insulin or sulfonylureas (increases the risk of hypoglycemia).
2. Oral drugs with narrow therapeutic window (such as warfarin, digoxin).
3. Levothyroxine : exposure increased by 33% when used in combination.
1. Store at room temperature (20-25°C).
2. Keep the original packaging moisture-proof and do not take out the tablets before use.